The SURGICEL® Powder Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding (China Study)

Inclusion Criteria

• Adult subjects aged ≥18 years requiring elective/non-emergent open or laparoscopic general, gynecological, or cardiothoracic surgical procedures.
• Subject or authorized representative has signed the approved Informed Consent.
• Subject(s) whose platelet count is ≥100, 000 per microliter and International Normalized Ratio (INR) is <1.5 prior to 24 hours of surgery.
• Presence of an appropriate TBS identified intra-operatively by the surgeon.
• Subject(s) undergoing cardiothoracic surgery with anticoagulation must have anticoagulation reversed prior to TBS identification and treatment.

Exclusion Criteria

• Female subjects who are pregnant or nursing.
• Subject on heparin within 12 hours prior to surgery, or oral Coumadin (warfarin) and/or Factor Xa inhibitors within 3 days prior to surgery.
• Subject on antiplatelet/P2Y12 inhibitors medication 5 days prior to surgery;
• Subject is currently participating or plans to participate in any other investigational product or drug trial without prior approval from the Sponsor.
• Subjects who are known, current alcohol and/or drug abusers.
• Subjects with any pre-operative findings identified by the surgeon that may preclude conduct of the study procedure.
• Subjects with any intra-operative findings identified by the surgeon that may preclude the use of study product.
• Subject with TBS in an actively infected field (Class III Contaminated or Class IV Dirty or Infected; see Appendix 1).
• TBS is on arteries or veins where application of SURGICEL Powder would present a risk of introducing the study product into an open blood vessel.
• Major arterial or venous bleeding or major defects in arteries and veins.
• TBS where silver nitrate or any other escharotic chemicals have been applied.
• TBS is in, around, or in proximity to foramina in bone, or areas of bony